Literature DB >> 23706550

Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin αvβ3 expression in vivo.

Leila Mirfeizi1, Joe Walsh, Hartmuth Kolb, Lachlan Campbell-Verduyn, Rudi A Dierckx, Ben L Feringa, Philip H Elsinga, Tjibbe de Groot, Ivan Sannen, Guy Bormans, Sofie Celen.   

Abstract

In the last few years click chemistry reactions, and in particular copper-catalyzed cycloadditions have been used extensively for the preparation of new bioconjugated molecules such as (18)F-radiolabeled radiopharmaceuticals for positron emission tomography (PET). This study is focused on the synthesis of the Siemens imaging biomarker [(18)F]RGD-K5. This cyclic peptide contains an amino acid sequence which is a well known binding motif for integrin αvβ3 involved in cellular adhesion to the extracellular matrix. We developed an improved "click" chemistry method using Cu(I)-Monophos as catalyst to conjugate [(18)F]fluoropentyne to the RGD-azide precursor yielding [(18)F]RGD-K5. A comparison is made with the registered Siemens method with respect to synthesis, purification and quality control. [(18)F]RGD-K5 was obtained after 75 min overall synthesis time with an overall radiochemical yield of 35% (EOB). The radiochemical purity was >98% and the specific radioactivity was 100-200 GBq/μmol at the EOS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706550     DOI: 10.1016/j.nucmedbio.2013.04.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  8 in total

1.  A novel PET tracer for targeted imaging of atherosclerosis.

Authors:  Eliana Reyes
Journal:  J Nucl Cardiol       Date:  2015-02-28       Impact factor: 5.952

2.  New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group.

Authors:  Kristin M Burns; Barry J Byrne; Bruce D Gelb; Bernhard Kühn; Leslie A Leinwand; Seema Mital; Gail D Pearson; Mark Rodefeld; Joseph W Rossano; Brian L Stauffer; Michael D Taylor; Jeffrey A Towbin; Andrew N Redington
Journal:  Circulation       Date:  2014-07-01       Impact factor: 29.690

Review 3.  Receptor Occupancy Imaging Studies in Oncology Drug Development.

Authors:  Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott
Journal:  AAPS J       Date:  2018-03-08       Impact factor: 4.009

4.  Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination.

Authors:  Falguni Basuli; Xiang Zhang; Carolyn C Woodroofe; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson
Journal:  J Labelled Comp Radiopharm       Date:  2017-02-01       Impact factor: 1.921

Review 5.  Click Chemistry and Radiochemistry: The First 10 Years.

Authors:  Jan-Philip Meyer; Pierre Adumeau; Jason S Lewis; Brian M Zeglis
Journal:  Bioconjug Chem       Date:  2016-11-22       Impact factor: 4.774

6.  Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of 18 F-Labeled PSMA-Tracers for Prostate Cancer Imaging.

Authors:  Verena I Böhmer; Wiktor Szymanski; Keimpe-Oeds van den Berg; Chantal Mulder; Piermichele Kobauri; Hugo Helbert; Dion van der Born; Friederike Reeβing; Anja Huizing; Marten Klopstra; Douwe F Samplonius; Ines F Antunes; Jürgen W A Sijbesma; Gert Luurtsema; Wijnand Helfrich; Ton J Visser; Ben L Feringa; Philip H Elsinga
Journal:  Chemistry       Date:  2020-07-21       Impact factor: 5.236

Review 7.  Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.

Authors:  Christine Rangger; Roland Haubner
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-30

Review 8.  PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments.

Authors:  Roland Haubner; Simone Maschauer; Olaf Prante
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.